Prime Medicine, Inc. Common Stock
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic therapies to address the spectrum of diseases by deploying gene editing technology in the United States. It offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that… Read more
Prime Medicine, Inc. Common Stock (PRME) - Total Liabilities
Latest total liabilities as of September 2025: $223.19 Million USD
Based on the latest financial reports, Prime Medicine, Inc. Common Stock (PRME) has total liabilities worth $223.19 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Prime Medicine, Inc. Common Stock - Total Liabilities Trend (2019–2024)
This chart illustrates how Prime Medicine, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Prime Medicine, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Prime Medicine, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tus-Sound Environmental Resources Co Ltd
SHE:000826
|
China | CN¥16.09 Billion |
|
Schoeller-Bleckmann Oilfield Equipment Aktiengesellschaft
PINK:SBOEF
|
USA | $540.24 Million |
|
Urban Company Limited
NSE:URBANCO
|
India | ₹4.27 Billion |
|
Shandong Kexing Bioproducts Co. Ltd. A
SHG:688136
|
China | CN¥1.70 Billion |
|
Ridley Corporation Limited
PINK:RIDYF
|
USA | $276.44 Million |
|
Boss Energy Ltd
AU:BOE
|
Australia | AU$54.15 Million |
|
Apollo Micro Systems Limited
NSE:APOLLO
|
India | ₹7.04 Billion |
|
Shinpoong Pharmaceutical Co Ltd
KO:019175
|
Korea | ₩77.39 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down Prime Medicine, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.61 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.38 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.58 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Prime Medicine, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Prime Medicine, Inc. Common Stock (2019–2024)
The table below shows the annual total liabilities of Prime Medicine, Inc. Common Stock from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $144.36 Million | +137.51% |
| 2023-12-31 | $60.78 Million | +38.00% |
| 2022-12-31 | $44.04 Million | -29.30% |
| 2021-12-31 | $62.30 Million | +192.35% |
| 2020-12-31 | $21.31 Million | +191.58% |
| 2019-12-31 | $7.31 Million | -- |